Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Kinetics of cholinesterase inhibition by eptastigmine in man

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Steel K, Feldman RG (1979) Diagnosing dementia and its treatable causes. Geriatrics 34: 79–88

  2. 2.

    Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215: 1237–1239

  3. 3.

    Reisine TD, Yamamura HI, Bird ED, Spokes E, Enna SJ (1978) Pre- and postsynaptic neurochemical alterations in Alzheimer's disease. Brain Res 149: 447–481

  4. 4.

    Davis KL, Mohs RC (1982) Enhancement of memory processes in Alzheimer's disease with multiple dose intravenous physostigmine. Am J Psychiat 139: 1421–1424

  5. 5.

    Schwartz AS, Kohlstaedt EV (1986) Physostigmine effects in Alzheimer's diseases: Relationship to dementia severity. Life Sci 38: 1021–1028

  6. 6.

    Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia of the Alzheimer type. N Engl J Med 315: 1241–1245

  7. 7.

    Brufani M, Marta M, Pomponi M (1986) Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia. Eur J Biochem 157: 115–120

  8. 8.

    De Sarno P, Pomponi M, Giacobini E, Tang XC, Williams E (1989) The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat. Neurochem Res 14: 971–977

  9. 9.

    Brufani M, Castellano C, Marta M, Oliverio A, Pagella PG, Pavone F, Pomponi M, Rugarli PL (1987) A long-lasting cholinesterase inhibitor affecting neural and behavioral processes. Pharm Biochem Behav 26: 625–629

  10. 10.

    Marta M, Castellano C, Oliverio A, Pavone F, Pagella PG, Brufani M, Pomponi M (1988) New analogs of physostigmine: alternative drugs for Alzheimer's disease? Life Sci 43: 1921–1928

  11. 11.

    Oliverio A, Castellano C, Iacopino C, Pavone F, Brufani M, Marta M, Pomponi M (1986) Effects of physostigmine derivatives on cerebral cholinergic functions and their possible use in Alzheimer disease. In: Biggio G, Spano PF, Toffano G and Gessa GL (eds) Modulation of Central and Peripheral Transmitter Function. Liviana Press, Padova, pp 305–309

  12. 12.

    Johnson CD, Russel RL (1975) A rapid, simple radiometric assay for cholinesterase, suitable for multiple determination. Anal Biochem 64: 229–238

  13. 13.

    Becker RE, Giacobini E (1988) Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological and therapeutic aspects. Drug Dev Res 12: 163–195

  14. 14.

    Becker RE, Colliver J, Elble R, Feldman E, Giacobini E, Kumar V, Markwell S, Moriearty P, Parks R, Shillcutt SD, Unni LK, Vicori S, Womack C, Zec R (1990) Effects of metrifonate, a long-acting cholinesterase inhibitor in Alzheimer disease: Report of an open trial. Drug Dev Res 19: 425–434

  15. 15.

    Lawrence GD, Yatim N (1990) Extraction of physostigmine from biologic fluids and analysis by liquid chromatography with electrochemical detection. J Pharmacol Methods 24: 137–143

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Unni, L.K., Hutt, V., Imbimbo, B.P. et al. Kinetics of cholinesterase inhibition by eptastigmine in man. Eur J Clin Pharmacol 41, 83–84 (1991). https://doi.org/10.1007/BF00280116

Download citation

Key words

  • Eptastigmine
  • cholinesterase inhibitor
  • Alzheimer's disease
  • pharmacokinetics
  • adverse effects